Stem Cell Clinic

Explosive Growth of IVIS Imaging Systems Market By 2027 Competitive Outlook By PerkinElmer Inc., Hallmarq Veterinary Imaging, CANON MEDICAL SYSTEMS…

By Stell Cell Research

Increasing prevalence of chronic diseases, aging population and demand of high resolution diagnostic methods are prime drivers for the market. Increasing cancer, cardiovascular, respiratory and other life threatening conditions in the developing countries are increasing demand for IVIS system in the forecast period. Moreover, increased research activities worldwide are creating lucrative opportunities for the market.

Leading IVIS Imaging Systems Market Players:

PerkinElmer Inc., Hallmarq Veterinary Imaging, CANON MEDICAL SYSTEMS CORPORATION, IDEXX, Shenzhen Mindray Bio-Medical Electronics Co., Ltd., ISHIDA CO.,LTD, FUJIFILM Holdings Corporation, Bruker Corporation, IMPERIAL LIFE SCIENCES (P) LIMITED

Get Sample Copy of this Report at: https://www.reportsweb.com/inquiry&RW00013350526/sample

The IVIS imaging system is noninvasive technique to monitor cell trafficking, gene expression, and disease progression. These are used in a variety of applications including oncology, infectious disease, musculoskeletal, cardiovascular, neurology, respiratory and stem cell research.

The Global IVIS Imaging Systems Market Analysis to 2027 is a specialized and in-depth study of the medical device industry with a special focus on the global market trend analysis. The report aims to provide an overview of IVIS Imaging Systems market with detailed market segmentation by type, end user, and geography. The global IVIS Imaging Systems market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading IVIS Imaging Systems market players and offers key trends and opportunities in the market.

Get Discount for This Report @ https://www.reportsweb.com/inquiry&RW00013350526/discount

The report covers key developments in the IVIS imaging systems market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from IVIS Imaging Systems market are anticipated to lucrative growth opportunities in the future with the rising demand for IVIS Imaging Systems market in the global market. Below mentioned is the list of few companies engaged in the IVIS Imaging Systems market.

Reason to Buy

Inquire for Report buying @ https://www.reportsweb.com/inquiry&RW00013350526/buying

Table of Content:

Market Overview

Competition Analysis by Players

Company (Top Players) Profiles

IVIS Imaging Systems Market Size by Type and Application

US Market Status and Outlook

EU Development Market Status and Outlook

Japan Market Development Status and Outlook

China Market Status and Outlook

India IVIS Imaging Systems Market Status and Outlook

Southeast Asia Market Status and Outlook

Market Forecast by Region, Type, and Application

Market Dynamics

Market Effect Factor Analysis

Research Finding/ Conclusion

Appendix

About ReportsWeb:

ReportsWeb.com is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries.

Contact Us:

Call: +1-646-491-9876 Email: [emailprotected]

Here is the original post:
Explosive Growth of IVIS Imaging Systems Market By 2027 Competitive Outlook By PerkinElmer Inc., Hallmarq Veterinary Imaging, CANON MEDICAL SYSTEMS...

Global Cell Culture Market 2020 | Scope of Current and Future Industry 2025 – 3rd Watch News

By Stell Cell Research

This report additionally covers the effect of COVID-19 on the worldwide market. The pandemic brought about by Coronavirus (COVID-19) has influenced each part of life all inclusive, including the business segment. This has brought along a several changes in economic situations.

The Latest Research Report on Cell Culture Market size | Industry Segment by Applications, by Type, Regional Outlook, Market Demand, Latest Trends, Cell Culture Industry Share & Revenue by Manufacturers, Company Profiles, Growth Forecasts 2025. Analyzes current market size and upcoming 5 years growth of this industry.

Download Sample Copy of the Report to understand the structure of the complete report (Including Full TOC, Table & Figures): http://marketresearchbazaar.com/requestSample/14980

Summary ICRWorlds Cell Culture market research report provides the newest industry data and industry future trends, allowing you to identify the products and end users driving Revenue growth and profitability. The industry report lists the leading competitors and provides the insights strategic industry Analysis of the key factors influencing the market. The report includes the forecasts, Analysis and discussion of important industry trends, market size, market share estimates and profiles of the leading industry Players. Global Cell Culture Market: Product Segment Analysis Classical Media & Salts Serum-free Media Stem Cell Media Global Cell Culture Market: Application Segment Analysis Biopharmaceutical Manufacturing Tissue Culture & Engineering Global Cell Culture Market: Regional Segment Analysis USA Europe Japan China India South East Asia The Players mentioned in our report Life Technologies Corning (Cellgro) Thermo Fisher Merck Millipore GE Healthcare Lonza BD HiMedia Takara Sigma-Aldrich BBI

Request Customization: http://marketresearchbazaar.com/enquiry/14980

Cell Culture Market: Regional Analysis

The report offers in-depth assessment of the growth and other aspects of the Cell Culture market in important regions, including the U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, Taiwan, Southeast Asia, Mexico, and Brazil, etc. Key regions covered in the report are North America, Europe, Asia-Pacific and Latin America.

The report has been curated after observing and studying various factors that determine regional growth such as economic, environmental, social, technological, and political status of the particular region. Analysts have studied the data of revenue, production, and manufacturers of each region. This section analyses region-wise revenue and volume for the forecast period of 2015 to 2025. These analyses will help the reader to understand the potential worth of investment in a particular region.

Key Strategic Developments:The study also includes the key strategic developments of the Cell Culturemarket, comprising R&D, new product launch, M&A, agreements, collaborations, partnerships, joint ventures, and regional growth of the leading competitors operating in the market on a global and regional scale.

Key Market Features:The report evaluated key market features, including revenue, price, capacity, capacity utilization rate, gross, production, production rate, consumption, market share, CAGR, and gross margin. Analytical Tools: The Cell Culture Market report includes the precisely studied and weighed data of the key industry players and their scope in the Cell Culture market by means of several analytical tools

About (Market Research Bazaar):

Market Research Bazaar (MRB)- a part of VRRB Reports LLP is an overall Market Research and consulting organization. We give unparalleled nature of offering to our clients present all around the world crosswise over industry verticals. Market Research Bazaar has aptitude in giving profound jump showcase understanding alongside advertise knowledge to our clients spread across over different endeavours.

Media Contact:

Market Research Bazaar

UK: +442070973908

US: +13156360953

India: +919548234540

Email:[emailprotected]

Website:http://marketresearchbazaar.com/

Blog:http://marketresearchbazaar.com/blogs

See the article here:
Global Cell Culture Market 2020 | Scope of Current and Future Industry 2025 - 3rd Watch News

Cord Blood Banking Market 2020: Global Industry Analysis By Size, Share, Growth, Trends And Forecast To 2026 – Cole of Duty

By Stell Cell Research

Trusted Business Insights answers what are the scenarios for growth and recovery and whether there will be any lasting structural impact from the unfolding crisis for the Cord Blood Banking market.

Trusted Business Insights presents an updated and Latest Study on Cord Blood Banking Market 2019-2026. The report contains market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market.The report further elaborates on the micro and macroeconomic aspects including the socio-political landscape that is anticipated to shape the demand of the Cord Blood Banking market during the forecast period (2019-2029). It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary, and SWOT analysis.

Get Sample Copy of this Report @ Cord Blood Banking Market Research Report Forecast to 2029 (Includes Business Impact of COVID-19)

Abstract, Snapshot, Market Analysis & Market Definition: Cord Blood Banking Market Industry / Sector Trends

Cord Blood Banking Market size was valued over USD 16 billion in 2018 and is expected to witness more than 5% CAGR from 2019 to 2025.

U.S. cord blood banking market, by type of bank, 2018 & 2025 (USD Million)

Growing prevalence of genetic disorders such as sickle cell anemia, thalassemia, cystic fibrosis, Tay-Sachs disease, haemophilia, fragile X syndrome and Huntingtons disease are the primary factor for the growth of cord blood banking market. As per the WHO estimates, about 2 million people in the U.S. are estimated to carry sickle cell allele. Growing burden of genetic disorders will drive the demand for cord blood transplantations in the future, thus fostering business growth.

Increasing awareness pertaining to various therapeutic applications of cord blood cells will serve as high impact rendering factor. Numerous government and private organizations are involved in creating awareness regarding numerous advantages of preservation of cord blood. For instance, In April 2015, BioInformant Worldwide partnered with Save the Cord Foundation to launch cord blood banking awareness campaign with an aim to educate expecting parents about the medical benefits of cord blood preservation. Aforementioned factors will be conducive to industry growth.

Market Segmentation, Outlook & Regional Insights: Cord Blood Banking Market

Cord Blood Banking Market, By Type of Bank

Germany cord blood banking market share, by type of bank, 2018

Private cord blood banks held majority share of the total market, accounting for revenue of USD 13.7 billion in 2018. Growing awareness among expectant parents as well as high demand to safeguard the health of family members by storing and preserving precious cord blood stem cells will drive the private cord blood banking market. Factors such as sufficient supply of cord blood along with guarantee for the availability of cells for transplantation in multiple relatives further will boost segmental growth.

Public cord blood banks are forecasted to expand at a CAGR of 6.1% from 2019 to 2025. Factors such as increase in the number and diversity of cord blood units available for patients and strong support from the federal and private funding will propel the demand for public cord blood banking, hence enhancing the segmental growth. Moreover, public banks are the primary source of cord blood cells for research professionals to investigate novel and potentially life-saving therapies for the patient population, thus propelling segment growth.

Cord Blood Banking Market, By Services

Processing service market segment accounted for USD 12.6 billion in 2018 and is expected to dominate the industry during the forecast timeframe. High growth is attributed to various technological advancements in cord blood processing methods. For instance, PrepaCyte-CB is a premium processing method of Cryo-Cell that provides better separation along with less crossover of the red and white cells. Contamination of red blood cells can be toxic and may lead to loss of precious cord blood cells during freezing. Removal of RBCs require processing, thus leading to segmental growth during the forecast period.

Storage service market segment will grow rapidly at 5.6% during the forecast timeframe. High growth is attributed to increasing number of expectant parents availing preservation of the new-borns cord blood cells. Additionally, various offers and discounts gives by private cord blood banks for long-term storage of cord blood cells of infants will significantly drive the storage services in the future.

Cord Blood Banking Market, By Application

Immuno-deficiency disorders is expected to grow at 5.6% in the upcoming years. Cord blood cells are increasingly being used for the treatment of primary immuno-deficiency disorders. Factors such as rapid and reliable recovery of immune function, low risk of graft versus host disease, and low viral transmission rate will boost the growth of the market for immuno-deficiency disorders treatment. In addition, government organizations are constantly providing funds along with spreading awareness related to stem cell transplants thus propelling segment growth.

Metabolic disorders segment accounted for USD 1.9 billion in 2018. Rising incidence of various metabolic disorders such as Krabbe leukodystrophy, Gunther Disease, Tay-Sachs disease will boost the application of cord blood cells for treatment of metabolic disorders. Cord blood cells are less reactive and more adaptable once they enter the patients body. Cord blood stem cell transplantation is the only effective treatment for the ailment in mildly affected late-onset patients and pre-symptomatic infantile patients, hence expanding the segment growth during the forecast timeframe.

Cord Blood Banking Market, By End-use

Hospitals segment accounted for revenue of USD 9.4 billion in 2018. Hospitals have a complete transplantation set up with latest technology and a highly experienced and qualified healthcare personnel. Furthermore, advancements in the field of cord blood banking and its growing popularity will consequently increase the application of cord blood transplantations in the near future. Increasing prevalence of genetic diseases and cancer around the globe is driving the hospitals market for cord blood treatment.

Specialty clinics segment held market share of 21.9% in 2018. Specialty clinics segment will have moderate growth rate due to increasing technological advancements that improve the quality of treatment related to cord blood transplantations. Major public and private banks facilitate cord blood units that are successfully used in the treatment of various form of cancer and genetic diseases, hence enhancing the segmental growth.

Cord Blood Banking Market, By Region

North America cord blood banking market share, by country, 2025 (USD Million)

North American market is expected to reach USD 6.9 billion by 2025. High growth rate is attributed to presence of large number of players operating in the country, thus augmenting market growth. Additionally, presence of large number of genetic disorders will further fuel the demand for cord blood cells market. Moreover, continuous efforts by researchers to explore new therapeutic applications of cord blood cells will spur market growth.

Asia Pacific cord blood banking market is forecasted to show growth of 6.7% from 2019 to 2025. High growth is attributable to increasing awareness regarding the advantages of preservation of cord blood cells across the developing economies of India and China. Additionally, these countries have great potential for growth due to comparatively higher birth rate. Furthermore, various market players are entering the developing nations to explore untapped opportunities, thus fostering business growth in the region.

Key Players, Recent Developments & Sector Viewpoints: Cord Blood Banking Market

Key industry players in global cord blood banking market are Singapore Cord Blood Bank, CBR Systems, ViaCord LLC, Cordlife, FamiCord, Cryo-Save, Americord, Global Cord Blood Corporation, LifeCell and Jeevan Stem Cell Foundation. Various strategies such as collaborations, acquisitions, mergers are undertaken by these players to strengthen market position.

Recent industry developments:

In April 2019, FamiCord Group announced the agreement of future business cooperation with CelluGen Biotech (India). This agreement will assist to generate beneficial synergies for both the companies in the field of family-based stem cell banking and the development of new stem cell-based drugs

In September 2018, CryoSave announced the introduction of its new storage facility in Geneva. This new safe and secure sample storage BioBank in its state-of-the-art central laboratory ensures a capacity of cryopreservation for more than millions of samples thus, increasing its storage facilities.

Cord Blood Banking Industry Viewpoint

Cord blood transplant can be traced back to the early 1990s when the first cord blood transplant was performed for treating T?cell leukemia. Since then, the technique underwent numerous advancements due to extensive R&D activities to explore new therapeutic implications. Currently cord blood is used for more than 80 therapeutic applications ranging from genetic disorders to metabolic disorders. In 2005, National Cord Blood Inventory (NCBI) was formed with the aim to increase the national supply of publicly donated cord blood units. Cord blood banking industry is expected to grow swiftly in the developing economies such as India and China due to high birth rate and growing healthcare infrastructure. Major market players are exploring the untapped opportunities to increase their market presence that will further boost cord blood banking industry.

Key Insights Covered: Exhaustive Cord Blood Banking Market 1. Market size (sales, revenue and growth rate) of Cord Blood Banking industry. 2. Global major manufacturers operating situation (sales, revenue, growth rate and gross margin) of Cord Blood Banking industry. 3. SWOT analysis, New Project Investment Feasibility Analysis, Upstream raw materials and manufacturing equipment & Industry chain analysis of Cord Blood Banking industry. 4. Market size (sales, revenue) forecast by regions and countries from 2019 to 2025 of Cord Blood Banking industry.

Research Methodology: Cord Blood Banking Market

Quick Read Table of Contents of this Report @ Cord Blood Banking Market Research Report Forecast to 2029 (Includes Business Impact of COVID-19)

Trusted Business Insights Shelly Arnold Media & Marketing Executive Email Me For Any Clarifications Connect on LinkedIn Click to follow Trusted Business Insights LinkedIn for Market Data and Updates. US: +1 646 568 9797 UK: +44 330 808 0580

Read the rest here:
Cord Blood Banking Market 2020: Global Industry Analysis By Size, Share, Growth, Trends And Forecast To 2026 - Cole of Duty

Capillary Electrophoresis Market Projection By Key Players, Status, Growth, Revenue, SWOT Analysis Forecast 2026 – 3rd Watch News

By Stell Cell Research

The Capillary Electrophoresis market report added recently by Analytical Research Cognizance, evaluates the industry in terms of market size, market share, revenue estimation, and geographical outlook. The study also delivers a precise summary that illustrates the competitive milieu, growth opportunities and application landscape of the Capillary Electrophoresis market depending on the industrys financial and non-financial impact.

The Capillary Electrophoresis market has witnessed growth from USD XX million to USD XX million from 2014 to 2019. With the CAGR of X.X%, this market is estimated to reach USD XX million in 2026.

The report mainly studies the size, recent trends and development status of the Capillary Electrophoresis market, as well as investment opportunities, government policy, market dynamics (drivers, restraints, opportunities), supply chain and competitive landscape. Technological innovation and advancement will further optimize the performance of the product, making it more widely used in downstream applications. Moreover, Porters Five Forces Analysis (potential entrants, suppliers, substitutes, buyers, industry competitors) provides crucial information for knowing the Capillary Electrophoresis market.

Download PDF Sample of Capillary Electrophoresis Market report @ https://www.arcognizance.com/enquiry-sample/941957

Major Players in the global Capillary Electrophoresis market include: Affymetrix, Inc. (US) Sartorius Stedim Biotech SA (France) A Becton, Dickinson and Company (US) Agilent Technologies, Inc. (US) Alfa Laval AB (Sweden) AB Sciex (US) 3M Purification, Inc. (US) GE Healthcare (UK) PerkinElmer, Inc. (US) Merck KGaA (Germany)

On the basis of types, the Capillary Electrophoresis market is primarily split into: Type 1 Type 2 Type 3

On the basis of applications, the market covers: Versatile Use Clinical Applications Research Applications Drug Discovery Biomedical Research Fetal Cell Separation Stem Cell Sorting Marine Biology and Environmental Sciences Microbiology

Brief about Capillary Electrophoresis Market Report with [emailprotected] https://www.arcognizance.com/report/global-capillary-electrophoresis-market-report-2019-competitive-landscape-trends-and-opportunities

Geographically, the report includes the research on production, consumption, revenue, market share and growth rate, and forecast (2014-2026) of the following regions: United States Europe (Germany, UK, France, Italy, Spain, Russia, Poland) China Japan India Southeast Asia (Malaysia, Singapore, Philippines, Indonesia, Thailand, Vietnam) Central and South America (Brazil, Mexico, Colombia) Middle East and Africa (Saudi Arabia, United Arab Emirates, Turkey, Egypt, South Africa, Nigeria) Other Regions

Chapter 1 provides an overview of Capillary Electrophoresis market, containing global revenue, global production, sales, and CAGR. The forecast and analysis of Capillary Electrophoresis market by type, application, and region are also presented in this chapter.

Chapter 2 is about the market landscape and major players. It provides competitive situation and market concentration status along with the basic information of these players.

Chapter 3 provides a full-scale analysis of major players in Capillary Electrophoresis industry. The basic information, as well as the profiles, applications and specifications of products market performance along with Business Overview are offered.

Chapter 4 gives a worldwide view of Capillary Electrophoresis market. It includes production, market share revenue, price, and the growth rate by type.

Chapter 5 focuses on the application of Capillary Electrophoresis, by analyzing the consumption and its growth rate of each application.

Chapter 6 is about production, consumption, export, and import of Capillary Electrophoresis in each region.

Chapter 7 pays attention to the production, revenue, price and gross margin of Capillary Electrophoresis in markets of different regions. The analysis on production, revenue, price and gross margin of the global market is covered in this part.

Chapter 8 concentrates on manufacturing analysis, including key raw material analysis, cost structure analysis and process analysis, making up a comprehensive analysis of manufacturing cost.

Chapter 9 introduces the industrial chain of Capillary Electrophoresis. Industrial chain analysis, raw material sources and downstream buyers are analyzed in this chapter.

Chapter 10 provides clear insights into market dynamics.

Chapter 11 prospects the whole Capillary Electrophoresis market, including the global production and revenue forecast, regional forecast. It also foresees the Capillary Electrophoresis market by type and application.

Chapter 12 concludes the research findings and refines all the highlights of the study.

Chapter 13 introduces the research methodology and sources of research data for your understanding.

Years considered for this report: Historical Years: 2014-2018 Base Year: 2019 Estimated Year: 2019 Forecast Period: 2019-2026

Single User License Copy and Other Purchase [emailprotected] https://www.arcognizance.com/purchase/941957

Some Point of Table of Content:

Chapter One: Capillary Electrophoresis Market Overview

Chapter Two: Global Capillary Electrophoresis Market Landscape by Player

Chapter Three: Players Profiles

Chapter Four: Global Capillary Electrophoresis Production, Revenue (Value), Price Trend by Type

Chapter Five: Global Capillary Electrophoresis Market Analysis by Application

Chapter Six: Global Capillary Electrophoresis Production, Consumption, Export, Import by Region (2014-2019)

Chapter Seven: Global Capillary Electrophoresis Production, Revenue (Value) by Region (2014-2019)

Chapter Eight: Capillary Electrophoresis Manufacturing Analysis

Chapter Nine: Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter Ten: Market Dynamics

Chapter Eleven: Global Capillary Electrophoresis Market Forecast (2019-2026)

Chapter Twelve: Research Findings and Conclusion

Chapter Thirteen: Appendixcontinued

To Check Discount of Capillary Electrophoresis Market @ https://www.arcognizance.com/discount/941957

List of tables List of Tables and Figures

Figure Capillary Electrophoresis Product Picture Table Global Capillary Electrophoresis Production and CAGR (%) Comparison by Type Table Profile of Type 1 Table Profile of Type 2 Table Profile of Type 3 Table Capillary Electrophoresis Consumption (Sales) Comparison by Application (2014-2026) Table Profile of Versatile Use Table Profile of Clinical Applications Table Profile of Research Applications Table Profile of Drug Discovery Table Profile of Biomedical Research Table Profile of Fetal Cell Separation Table Profile of Stem Cell Sorting Table Profile of Marine Biology and Environmental Sciences Table Profile of Microbiology Figure Global Capillary Electrophoresis Market Size (Value) and CAGR (%) (2014-2026) Figure United States Capillary Electrophoresis Revenue and Growth Rate (2014-2026) Figure Europe Capillary Electrophoresis Revenue and Growth Rate (2014-2026) Figure Germany Capillary Electrophoresis Revenue and Growth Rate (2014-2026) Figure UK Capillary Electrophoresis Revenue and Growth Rate (2014-2026) Figure France Capillary Electrophoresis Revenue and Growth Rate (2014-2026) Figure Italy Capillary Electrophoresis Revenue and Growth Rate (2014-2026) Figure Spain Capillary Electrophoresis Revenue and Growth Rate (2014-2026) Figure Russia Capillary Electrophoresis Revenue and Growth Rate (2014-2026) Figure Poland Capillary Electrophoresis Revenue and Growth Rate (2014-2026) Figure China Capillary Electrophoresis Revenue and Growth Rate (2014-2026) Figure Japan Capillary Electrophoresis Revenue and Growth Rate (2014-2026) Figure India Capillary Electrophoresis Revenue and Growth Rate (2014-2026) Figure Southeast Asia Capillary Electrophoresis Revenue and Growth Rate (2014-2026) Figure Malaysia Capillary Electrophoresis Revenue and Growth Rate (2014-2026) Figure Singapore Capillary Electrophoresis Revenue and Growth Rate (2014-2026) Figure Philippines Capillary Electrophoresis Revenue and Growth Rate (2014-2026) Figure Indonesia Capillary Electrophoresis Revenue and Growth Rate (2014-2026) Figure Thailand Capillary Electrophoresis Revenue and Growth Rate (2014-2026) Figure Vietnam Capillary Electrophoresis Revenue and Growth Rate (2014-2026) Figure Central and South America Capillary Electrophoresis Revenue and Growth Rate (2014-2026) Figure Brazil Capillary Electrophoresis Revenue and Growth Rate (2014-2026) Figure Mexico Capillary Electrophoresis Revenue and Growth Rate (2014-2026) Figure Colombia Capillary Electrophoresis Revenue and Growth Rate (2014-2026) Figure Middle East and Africa Capillary Electrophoresis Revenue and Growth Rate (2014-2026) Figure Saudi Arabia Capillary Electrophoresis Revenue and Growth Rate (2014-2026) Figure United Arab Emirates Capillary Electrophoresis Revenue and Growth Rate (2014-2026) Figure Turkey Capillary Electrophoresis Revenue and Growth Rate (2014-2026) Figure Egypt Capillary Electrophoresis Revenue and Growth Rate (2014-2026) Figure South Africa Capillary Electrophoresis Revenue and Growth Rate (2014-2026) Figure Nigeria Capillary Electrophoresis Revenue and Growth Rate (2014-2026) Figure Global Capillary Electrophoresis Production Status and Outlook (2014-2026) Table Global Capillary Electrophoresis Production by Player (2014-2019) Table Global Capillary Electrophoresis Production Share by Player (2014-2019) Figure Global Capillary Electrophoresis Production Share by Player in 2018 Table Capillary Electrophoresis Revenue by Player (2014-2019) Table Capillary Electrophoresis Revenue Market Share by Player (2014-2019) Table Capillary Electrophoresis Price by Player (2014-2019) Table Capillary Electrophoresis Manufacturing Base Distribution and Sales Area by Player Table Capillary Electrophoresis Product Type by Player Table Mergers & Acquisitions, Expansion Plans Table Affymetrix, Inc. (US) Profile Table Affymetrix, Inc. (US) Capillary Electrophoresis Production, Revenue, Price and Gross Margin (2014-2019) Table Sartorius Stedim Biotech SA (France) Profile Table Sartorius Stedim Biotech SA (France) Capillary Electrophoresis Production, Revenue, Price and Gross Margin (2014-2019) Table A Profile Table A Capillary Electrophoresis Production, Revenue, Price and Gross Margin (2014-2019) Table Becton, Dickinson and Company (US) Profile Table Becton, Dickinson and Company (US) Capillary Electrophoresis Production, Revenue, Price and Gross Margin (2014-2019) Table Agilent Technologies, Inc. (US) Profile Table Agilent Technologies, Inc. (US) Capillary Electrophoresis Production, Revenue, Price and Gross Margin (2014-2019) Table Alfa Laval AB (Sweden) Profile Table Alfa Laval AB (Sweden) Capillary Electrophoresis Production, Revenue, Price and Gross Margin (2014-2019) Table AB Sciex (US) Profile Table AB Sciex (US) Capillary Electrophoresis Production, Revenue, Price and Gross Margin (2014-2019) Table 3M Purification, Inc. (US) Profile Table 3M Purification, Inc. (US) Capillary Electrophoresis Production, Revenue, Price and Gross Margin (2014-2019) Table GE Healthcare (UK) Profile Table GE Healthcare (UK) Capillary Electrophoresis Production, Revenue, Price and Gross Margin (2014-2019) Table PerkinElmer, Inc. (US) Profile Table PerkinElmer, Inc. (US) Capillary Electrophoresis Production, Revenue, Price and Gross Margin (2014-2019) Table Merck KGaA (Germany) Profile Table Merck KGaA (Germany) Capillary Electrophoresis Production, Revenue, Price and Gross Margin (2014-2019) Table Global Capillary Electrophoresis Production by Type (2014-2019) Table Global Capillary Electrophoresis Production Market Share by Type (2014-2019) Figure Global Capillary Electrophoresis Production Market Share by Type in 2018 Table Global Capillary Electrophoresis Revenue by Type (2014-2019) Table Global Capillary Electrophoresis Revenue Market Share by Type (2014-2019) Figure Global Capillary Electrophoresis Revenue Market Share by Type in 2018 Table Capillary Electrophoresis Price by Type (2014-2019) Figure Global Capillary Electrophoresis Production Growth Rate of Type 1 (2014-2019) Figure Global Capillary Electrophoresis Production Growth Rate of Type 2 (2014-2019) Figure Global Capillary Electrophoresis Production Growth Rate of Type 3 (2014-2019) Table Global Capillary Electrophoresis Consumption by Application (2014-2019) Table Global Capillary Electrophoresis Consumption Market Share by Application (2014-2019) Table Global Capillary Electrophoresis Consumption of Versatile Use (2014-2019) Table Global Capillary Electrophoresis Consumption of Clinical Applications (2014-2019) Table Global Capillary Electrophoresis Consumption of Research Applications (2014-2019) Table Global Capillary Electrophoresis Consumption of Drug Discovery (2014-2019) Table Global Capillary Electrophoresis Consumption of Biomedical Research (2014-2019) Table Global Capillary Electrophoresis Consumption of Fetal Cell Separation (2014-2019) Table Global Capillary Electrophoresis Consumption of Stem Cell Sorting (2014-2019) Table Global Capillary Electrophoresis Consumption of Marine Biology and Environmental Sciences (2014-2019) Table Global Capillary Electrophoresis Consumption of Microbiology (2014-2019) Table Global Capillary Electrophoresis Consumption by Region (2014-2019) Table Global Capillary Electrophoresis Consumption Market Share by Region (2014-2019) Table United States Capillary Electrophoresis Production, Consumption, Export, Import (2014-2019) Table Europe Capillary Electrophoresis Production, Consumption, Export, Import (2014-2019) Table China Capillary Electrophoresis Production, Consumption, Export, Import (2014-2019) Table Japan Capillary Electrophoresis Production, Consumption, Export, Import (2014-2019) Table India Capillary Electrophoresis Production, Consumption, Export, Import (2014-2019) Table Southeast Asia Capillary Electrophoresis Production, Consumption, Export, Import (2014-2019) Table Central and South America Capillary Electrophoresis Production, Consumption, Export, Import (2014-2019)continued

If you have any special requirements, please let us know and we will offer you the report as you want.

Our trending Report Links: Global Coatings For Medical Devices Market Report 2019, Competitive Landscape, Trends and [emailprotected] https://www.marketwatch.com/press-release/coatings-for-medical-devices-market-growth-industry-trends-2020-size-by-regions-global-industry-share-sales-revenue-and-opportunities-till-2026-with-covid-19-impact-2020-05-27

Global Population Health Management Systems Market Professional Survey 2019 by Manufacturers, Regions, Types and Applications, Forecast to [emailprotected] https://www.marketwatch.com/press-release/population-health-management-systems-market-share-size-type-demand-trends-analysis-growth-applications-research-emerging-technologies-opportunities-till-2024-with-covid-19-impact-2020-05-27

About Us:Analytical Research Cognizance (ARC)is a trusted hub for research reports that critically renders accurate and statistical data for your business growth. Our extensive database of examined market reports places us amongst the best industry report firms. Our professionally equipped team further strengthens ARCs potential.

ARC works with the mission of creating a platform where marketers can have access to informative, latest and well researched reports. To achieve this aim our experts tactically scrutinize every report that comes under their eye.

Contact Us: Ranjeet Dengale Director Sales Analytical Research Cognizance Office no, 201, 2nd Floor, Jachak Chambers, Pimple Saudagar, Pune 411027, Maharashtra, India +1 (646) 403-4695, +91 90967 44448 Email: [emailprotected]

Follows to Twitter : https://twitter.com/ARCognizance

Follows to Linkdin : https://www.linkedin.com/company/arcognizance

Continue reading here:
Capillary Electrophoresis Market Projection By Key Players, Status, Growth, Revenue, SWOT Analysis Forecast 2026 - 3rd Watch News

Stem cell study aims to fight the COVID-19 ‘storm’ – Cayman Compass

By Stem Cell Medicine

Residents of the Caribbean know that between a tropical storm and a major hurricane, there is a world of difference. Both bring rain and winds, but weathering and surviving a hurricane requires much greater response and resilience.

Dr. Javier Perez Fernandez, a specialist in critical care medicine and pulmonology at Baptist Health South Florida, views COVID-19 infections in a similar way. While some hospitalised patients face a tropical storm, others are battling a category five hurricane.

Through a new stem cell treatment, Perez says doctors at Baptist Health and Miami Cancer Institute hope to control the magnitude of COVID-19 storms and mitigate the viruss effects in the most severely affected patients.

As researchers worldwide work against the clock to fight the novel coronavirus, Perez views the stem cell treatment as one with potential for wide-spread adoption, including use in the Cayman Islands.

It converts this category five hurricane that you have inside into a tropical storm, Perez said, explaining that while the treatment cannot cure the virus, it may save lives.

The investigational drug, developed from sentinel or original cells attached to the umbilical cord, takes aim at another kind of storm, produced when the bodys immune system goes into overdrive.

A cytokine storm, seen in fatal COVID-19 cases, occurs when cytokine molecules are released by the body as an immune system response to fight infection. An excessive release of these molecules can result in hyperinflammation, organ failure and death.

With a stem cell injection, however, Perez says doctors have been able to control this cytokine storm and reduce COVID-19 impacts, such as respiratory distress.

As the cytokine storms really affect the lungs, mostly weve seen significant changes on oxygenation of people while we are delivering the cells, Perez said.

Weve seen very good responses on the patients that we have infused, and we have seen responses that lead to a reduction in the oxygen level [administered] by 50% of what they were using.

The studys results are still not ready to disclose, and Perez said the rate of research is contingent on the number of patients admitted to critical care units at partner facilities.

In that sense, he hopes the study will remain unfinished, due to a lack of severely ill patients.

I think the main limitation for faster development has been the lower number of patients that we have on intensive care units, he said.

The stem cell study has incorporated partners from several US universities, including Florida International University and University of South Dakota, and RESTEM, a California biotechnology company that develops treatments for degenerative and immune system disorders.

Once the treatment has gone through the full development and approval process, Perez sees Cayman as one of the locations that could benefit from its use.

Well be absolutely happy [to bring] not only that treatment but any other form of treatment, to be there for the people of Cayman, Perez said.

During the 17 June press briefing, Caymans chief medical officer Dr. John Lee mentioned another novel COVID-19 treatment, a steroid called dexamethasone, that is showing promise in the United Kingdom.

Its been shown to reduce deaths by up to a third and has already received approval for emergency use in the United Kingdom, Lee said, adding that he anticipates the drug will be approved and made available elsewhere.

The drug, developed by scientists at the University of Oxford, is the first treatment shown to aid severely ill COVID-19 patients. Similar to the stem cell treatment being studied by Baptist Health, dexamethasone treatment aims to reduce the effects of cytokine storms and mitigate the potentially deadly impact of an uncontrolled immune system response.

If you value our service, if you have turned to us in the past few days or weeks for verified, factual updates, if you have watched our live streaming of press conferences or sent an article to a friend... please consider a donation. Quality local journalism was at risk before the coronavirus crisis. It is now deeply threatened. Even a small amount can go a long way to sustaining our mission of informing the public. We need our readers financial support now more than ever.

Follow this link:
Stem cell study aims to fight the COVID-19 'storm' - Cayman Compass

Cell and gene therapy-focused OpenCell Technologies hires MilliporeSigma executive Kevin Gutshall as new CEO – Webster County Citizen

By Stem Cell Medicine

ST. LOUIS, June 18, 2020 /PRNewswire/ -- OpenCell Technologies, an R&D-stage biomedical venture, has announced the hiring of Kevin Gutshall as CEO. Kevin leaves his role as MilliporeSigma's director of life science business development and M&A focusing on the cell and gene therapy business unit, to join OpenCell and lead its efforts to translate and commercialize its core technology platform, POROS.

OpenCell was established based on technology developed at the Georgia Institute of Technology, by Engineering faculty and company co-founders Mark Meacham, PhD, Andrei Fedorov, PhD, and Levent Degertekin, PhD. Dr. Meacham was subsequently recruited to Washington University in St. Louis, and OpenCell relocated to the BioGenerator Labs in the Cortex Innovation Community adjacent to the Washington University School of Medicine. The company's core technology, which has broad applications ranging from fuel and energy to life sciences, is focused on the rapidly emerging cell and gene therapy market.

"I am thrilled to join OpenCell, as it is now poised to move from an R&D stage to a commercial business," said Gutshall. "I believe that the POROS platform will be a disruptive technology platform in the cell and gene therapy marketplace."

During its seed stage, the company benefitted from BioGenerator Entrepreneurs-in-Residence (EIR) that brought key expertise to the company as it pivoted from the research tools market to cell and gene therapy applications. Paul Olivo, MD, PhD, a former BioGenerator EIR and current Venture Partner at Synchrony Bio, which also participated in the current financing, serves as a key advisor to OpenCell, managing the company's research team. In her role as BioGenerator EIR, Heather Holeman, PhD, now CEO of Lifespan Biosciences, facilitated key business development connections for the company. Concurrent with the financing, Charlie Bolten, Senior Vice President of BioGenerator, joins OpenCell's board of directors.

"Together with Synchrony Bio, BioGenerator's investment in OpenCell is the culmination of extensive due diligence and hands-on support by our investment, Entrepreneur-in-Residence and Grants-2-Business teams," said Bolten. "With the successful recruitment of a CEO with deep experience in commercialization, business development and M&A, we are pleased to see OpenCell take an important step toward commercializing the POROS platform."

"I am excited to welcome Kevin as the new CEO of OpenCell," added Chad Stiening, OpenCell Executive Chairman and Managing Director at Synchrony Bio. "His professional background and personal passion in the cell and gene therapy space is a perfect fit for the company as it seeks to realize the full potential of its technology and enable the development and manufacturing of promising new therapies in this dynamic market."

In addition to investments from BioGenerator and Synchrony Bio, the company has leveraged significant Federal grant funding over $3M total to help secure equity financing and achieve key milestones that helped attract strategic partnering interest as well as its new CEO.

About OpenCellOpenCell Technologies provides efficient, high-throughput and scalable transfection tools to the Life Science Industry, enabling it to use difficult-to-transfect cells (e.g., primary and cancer stem cell cultures) in development of cell-based analysis techniques and discovery of new therapeutic cell-based therapies. Unlike currently available products, the OpenCell technology features precise control of biophysical actions on a single-cell basis without sacrificing throughput. OpenCell's vision is to realize a novel, cost-effective approach to transfection that will overcome existing research and development obstacles.Our mission is to make cellular therapies effective, affordable and scalable for the clinical and research communities. Visit opencelltech.com for more information.

About BioGenerator BioGenerator, the investment arm of BioSTL, produces a sustained pipeline of successful bioscience companies and entrepreneurs in St.Louis by creating, growing and investing in promising new enterprises. Visit biogenerator.org for additional information, and follow us on LinkedIn and Twitter.

About Synchrony BioSynchrony Bio seeks to achieve consistently superior investor returns in early-stage biomedical and life science ventures by aligning seasoned talent, staged investment capital, and process efficiencies.Careful and coordinated alignment of all three is key to overcoming unique challenges faced by medical device and diagnostics ventures, in order to realize significant upside and superior returns.Synchrony's extended network of experts and advisors includes professionals with deep, cross-functional experience and backgrounds. Visit synchronybio.com for additional information.

Go here to read the rest:
Cell and gene therapy-focused OpenCell Technologies hires MilliporeSigma executive Kevin Gutshall as new CEO - Webster County Citizen

Orca Bio Surfaces With $192M and Recipes for Custom Cell Therapies – Xconomy

By Stem Cell Medicine

Xconomy San Francisco

The cancer cell therapies available today are made by tweaking a patients own immune cells to better recognize and fight the disease. Orca Bio is developing what it says is the next generation of cell therapy: custom preparations made without modifying cells or genes.

Orca is already testing its technology in humans, though it has kept that research mostly under wraps. As the startup prepares to reveal its preliminary findings and ramp up its manufacturing capability, the Menlo Park, CA-based biotechannounced on Wednesday the close of $192 million in financing.

The immune system is comprised of many cells that work in concert, says CEO Ivan Dimov. Some cells stimulate activity while other cells block it. But the effects of these immune cells can be dampened by the other cells around them. Orcas therapies are allogeneictheyre made by taking stem and immune cells from healthy donors rather than from the patients themselves, as is the case with autologous treatments. But rather than just taking those healthy cells and putting them into a patient, Orca chooses certain cells from the donor sample and combines them in specific ways. Dimov says each mixture, created from certain cell types that it has assembled in the proper ratio, forms a custom immune army that seeks out cancer cells and leaves healthy tissue alone.

Weve created a novel class of precision therapiesprecise, optimal therapeutic mixtures, he says.

Orcas first disease targets are aggressive blood cancers that require bone marrow transplants as a treatment of last resort. These procedures offer patients a potential cure, but they also come with risks, such as rejection by the immune system.

In recent years, cell therapy has emerged as a new option for aggressive blood cancers that havent responded to treatment. Chimeric antigen receptor T cell therapies, or CAR-Ts, are made by engineering a patients own T cells, multiplying them in a lab, and then infusing them back into the patient to target and fight the cancer. The first CAR-Ts that reached the market were developed by Novartis (NYSE: NVS) and Gilead Sciences (NASDAQ: GILD). These therapies pose the risk of a potentially fatal immune system reaction.

There are other biotechs that are trying to advance CAR-T therapy by making it safer and more scalable. Some of them, like Orca, are developing allogeneic cell therapies. Two such companies, Allogene Therapeutics (NASDAQ: ALLO) and Precision Biosciences (NASDAQ: DTIL), use gene editing to eliminate parts of an immune cell that could prompt an adverse response. Those companies are testing their respective therapies in clinical trials.

Dimov says Orcas custom therapies are meant to allow patients to avoid the complications associated with bone marrow transplants and CAR-T drugs. The descriptor custom needs a bit of clarification: An Orca therapy is not tailored to each patient, but rather customized to generate a particular therapeutic effect, Dimov says. If it works, the right mix not only provides the optimal treatment, it also avoids any adverse immune response. This approach offers a new way to reset and rebuild the immune system, Dimov says.

Orca has two programs in clinical trials. TRGFT-201 is a formulation of T cells and regulatory T cells (a type of cell that tamps down an immune response) that is in Phase 1/2 testing in patients with certain blood cancers. A second program, OGFT-0001, is a formulation of T cells that is in Phase 1, also in blood cancers. The new cash is expected to be enough for Orca to complete Phase 1 tests of the lead program, as well as build the startups manufacturing capacity.

Preliminary data from the studies have not yet been reported but Dimov says a terminally ill cancer patient who received one of the Orca therapies got well enough to leave the hospital. Anecdote aside, while full data are expected in 2022, some early findings are being prepared for peer review.

Orca traces its origins to the laboratory of Irv Weissman, director of the Stanford Institute for Stem Cell Biology and Regenerative Medicine. Dimov joined Weissmans group in 2010 as the field of cell therapy was heating up. At that time, a central obstacle to its progress was figuring out how to make cell therapy manufacturing scalable. Meanwhile, the scientific communitys understanding of immune cells continued to advance. Orcas intellectual property covers both the cell therapy manufacturing technology, which offers the capability to sort stem and immune cells, and the therapeutic mixtures of cells. The startup spun out of Stanford in 2016 and started its first clinical trial about two years later, Dimov says.

Though cancer is Orcas focus for now, Dimov says the companys technology has potential applications in other diseases. Rare inherited disorders such as beta thalassemia and severe combined immunodeficiency are possible targets. Autoimmune diseases represent another opportunity. For each one, Orca would develop an appropriate mixture of immune and stem cells to treat the condition and restore immune system function, Dimov says.

Including the latest financing, Dimov says Orca has raised nearly $300 million. The new capital, a Series D round of funding, was co-led by Lightspeed Venture Partners and an unnamed investor. The other investors Orca has disclosed are 8VC, DCVC Bio, ND Capital, Abu Dhabi sovereign wealth fund Mubadala Investment Company, Kaiser Permanente, and the Illinois Municipal Retirement Fund.

Image: iStock/jonmccormackphoto

Frank Vinluan is an Xconomy editor based in Research Triangle Park. You can reach him at fvinluan@xconomy.com.

View post:
Orca Bio Surfaces With $192M and Recipes for Custom Cell Therapies - Xconomy

COVID 19 Impact on REGENERATIVE MEDICINE MARKET 2020 GLOBAL INDUSTRY SIZE, ANALYSIS, FUTURE GROWTH, TYPES, END-USERS, KEY PLAYERS AND REGIONAL…

By Stem Cell Medicine

The Global Regenerative Medicine Market increasing adoption of stem cell technology, growing prevalence of chronic diseases, and emerging applications of gene therapy in regenerative medicine are some of the driving factors for the global regenerative medicine market.A number of factors, such as the government and private funding to support the development of regenerative medicine, rising prevalence of chronic diseases and genetic disorders, increase in global healthcare expenditure, and rapid growth in the aging population are expected to drive the growth of this market. Click to Access Sample Pages @https://www.orianresearch.com/request-sample/722408Ethical concerns with the use of embryonic stem cell for r&d, lack of clear regulatory guideline are some of major factors which can hamper the growth of the market.

Rising Demand for Organ Transplantation and Strong Product Pipeline are some of the opportunitites in the forecast period.

Based on therapy the market is segmented into cell therapy, gene therapy, tissue engineering, immunotherapy. The cell-based products is expected to dominate the global Regenerative Medicine market in 2016. Increasing funding from several agencies and private organizations for the research and development of cell therapies, growing inclination of the healthcare industry towards stem cell research, and increasing global awareness about the benefits of stem cell therapies are driving the growth of the cell therapy segment.

Based on application the market is segmented into, Orthopedic & Musculoskeletal Disorders, Dermatology, Oncology, Cardiology

North America dominates the regenerative medicine market due to rapid technological advancements and high investment & funding to support development of regenerative medicine. Asia-Pacific is also expected to propel the regenerative medicine market, owing to factors, such as increasing accessibility to healthcare facilities in the region, and surging economic growth.

Some of the key players operating in this market includeOrganogenesis Inc. (U.S.), Osiris Therapeutics, Inc. (U.S.), Vericel Corporation (U.S.), Stryker Corporation (U.S.), and NuVasive, Inc. (U.S.). The key players in the acellular products segment are Medtronic (Ireland), Acelity (KCI Concepts) (U.S.), Integra LifeSciences (U.S.), Cook Biotech Inc. (U.S.), and C.R. Bard (U.S.).

Key Benefits of the Report:

* Global, Regional, Country, Therapy, and APPLICATION Market Size and Forecast from 2014-2025

* Detailed market dynamics, industry outlook with market specific PESTLE, Value Chain, Supply Chain, and SWOT Analysis to better understand the market and build strategies

* Identification of key companies that can influence this market on a global and regional scale

* Expert interviews and their insights on market shift, current and future outlook and factors impacting vendors short term and long term strategies

* Detailed insights on emerging regions, Therapy& Application, and competitive landscape with qualitative and quantitative information and facts.

Global Regenerative Medicine Industry 2020 Market Research Report is spread across 121 pages and provides exclusive vital statistics, data, information, trends and competitive landscape details in this niche sector.

Inquire more or share questions if any before the purchase on this report @https://www.orianresearch.com/enquiry-before-buying/722408

Target Audience:

* Regenerative Medicine providers

* Traders, Importer and Exporter

* Raw material suppliers and distributors

* Research and consulting firms

* Government and research organizations

* Associations and industry bodies.

The Report Covers Exhaustive Analysis on:

The market estimates and forecasts have been verified through exhaustive primary research with the Key Industry Participants (KIPs) which typically include:

* Original Manufacturer,

* Therapy Supplier,

* Distributors,

* Government Body & Associations, and

* Research Institute.

Order a Copy of Global Regenerative Medicine Market Report @https://www.orianresearch.com/checkout/722408

TABLE OF CONTENT

1 Executive Summary

2 Methodology And Market Scope

3 Regenerative Medicine Market Industry Outlook

4 Regenerative Medicine Market By Product Type

5 Regenerative Medicine Market Application Type

6 Regenerative Medicine Market Regional

7 Competitive Landscape

End Of The Report

Disclaimer

Customization Service of the Report: Orian Research provides customization of reports as per your need. This report can be personalized to meet your requirements. Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.

About Us:

Orian Research is one of the most comprehensive collections of market intelligence reports on the World Wide Web. Our reports repository boasts of over 500000+ industry and country research reports from over 100 top publishers. We continuously update our repository so as to provide our clients easy access to the worlds most complete and current database of expert insights on global industries, companies, and products. We also specialize in custom research in situations where our syndicate research offerings do not meet the specific requirements of our esteemed clients.

Go here to see the original:
COVID 19 Impact on REGENERATIVE MEDICINE MARKET 2020 GLOBAL INDUSTRY SIZE, ANALYSIS, FUTURE GROWTH, TYPES, END-USERS, KEY PLAYERS AND REGIONAL...

Inhibition of Migration, Invasion and Drug Resistance of Pancreatic Ad | OTT – Dove Medical Press

By Stem Cell Medicine

Ezgi Kakc,1,2 Esra Aydemir,1 mer Faruk Bayrak,3 Fikrettin ahin1

1Department of Genetics and Bioengineering, Faculty of Engineering and Architecture, Yeditepe University, Istanbul 34755, Turkey; 2Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY 10461, USA; 3Department of Medical Genetics, Yeditepe University Medical School and Yeditepe University Hospital, Istanbul 34718, Turkey

Correspondence: Ezgi Kakc Email ezgikasikci13@gmail.com

Purpose: The main purpose of this study is to demonstrate the effects of epithelial to mesenchymal transition activating transcription factor silencing (EMT-ATF silencing) on migration, invasion, drug resistance and tumor-forming abilities of various pancreatic cancer cell lines. Additionally, the contribution of small molecule inhibitors of EMT (SD-208 and CX4945) to the effects of gene silencing was evaluated. Methods: EMT activating transcription factors Snail, Slug and Twist were silenced by short hairpins on Panc-1, MIA PaCa-2, BxPC-3, and AsPC-1 pancreatic cancer cell lines. The changes in migration, invasion, laminin attachment, cancer stem-like cell properties and tumor-forming abilities were investigated. Chemosensitivity assays and small molecule inhibitors of EMT were applied to the metastatic pancreatic cancer cell line AsPC-1. Results: EMT-ATF silencing reduced EMT and stem cell-like characteristics of pancreatic cancer cell lines. Following EMT-ATF silencing amongst the four PC cell lines, AsPC-1 showed the best response and was chosen for further chemoresistance and combinational therapy applications. EMT downregulated AsPC-1 cells showed less resistance to select chemotherapeutics compared to the control group. Both small molecule inhibitors enhanced the outcomes of EMT-ATF silencing. Conclusion: Overall it was found that EMT-ATF silencing, either by EMT-ATF silencing or with the enhancement by small molecules, is a good candidate to treat pancreatic cancer since it simultaneously minimizes metastasis, stem cell properties, and drug resistance.

Keywords: pancreatic cancer, metastasis, cancer, EMT, gene therapy, anti-cancer drug

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

See the original post here:
Inhibition of Migration, Invasion and Drug Resistance of Pancreatic Ad | OTT - Dove Medical Press

Tiziana Life Sciences outlines a busy schedule for 2020 – Proactive Investors USA & Canada

By Stem Cell Medicine

Tiziana Life Sciences PLC (LON:TILS, NASDAQ:TLSA) has outlined a busy schedule for 2020 after making significant clinical and pre-clinical progress with assets spanning cancers, autoimmune and inflammatory diseases.

The update was provided alongside full-year results for the 12 months to December 31, 2019.

In the outlook statement, the company said preclinical studies are ongoing for its new technology to treat coronavirus (COVID-19) infections. Its approach consists of the direct delivery of anti-IL-6 receptor monoclonal antibodies into the lungs using a handheld inhaler or nebuliser. Additionally, Tiziana said it hopes to commence a trial investigating the direct delivery of an anti-IL-6 mAb to the lungs using a portable inhaler.

Turning to Foralumab, based on successful phase I data, the company said it intends to conduct a phase II study using Crohn's Disease patients starting in the second half of this year. A study of the use of the nasally-administered drug in multiple sclerosis patients is also planned. Pre-clinical work is planned around a potential breakthrough use in Alzheimers.

For Milciclib, the company is planning a phase IIb clinical trial in HCC (liver cancer) patients with the drug being used in combination with a Tyrosine kinase inhibitors such as Regorafenib or Sorafenib.

Looking ahead, Tiziana is confident that it is well-positioned to advance these programs to their next respective value inflection points, chairman Gabriele Cerrone said in the results statement.

Tiziana also said it is continuing with the development of its StemPrint ER diagnostic tester. The stem cell-based genomic prognostic tool has been shown to be clinically superior to the standard of care, a technology called Oncotype DX, in predicting recurrence in ER+/HER2- postmenopausal breast cancer patients.

In May, the company said it was planning to spin out its StemPrintER and SPARE genomics-based personalised medicine businesses as a separate stock market quoted company.

This will allow the newly independent group to secure independent funding to accelerate the accelerated development of the StemPrintER genomic test, the group said. It will also ensure the demerged entity can focus solely on the personalised medicines market.

Turning to the financials, Tiziana, as would be expected of a company focused solely on research and development, was loss-making to the tune of 7.17mln in 2019.

R&D costs shrunk to 2.9mln from 4.1mln as the Miciclib phase IIa trial was completed.

It bolstered its cash reserves in March with a 7.8mln (U$10mln) offering of American depositary shares.

Read the original here:
Tiziana Life Sciences outlines a busy schedule for 2020 - Proactive Investors USA & Canada

→←